key: cord-0714263-obhm5mc5
authors: Bertoglio, Federico; Meier, Doris; Langreder, Nora; Steinke, Stephan; Rand, Ulfert; Simonelli, Luca; Heine, Philip Alexander; Ballmann, Rico; Schneider, Kai-Thomas; Roth, Kristian Daniel Ralph; Ruschig, Maximilian; Riese, Peggy; Eschke, Kathrin; Kim, Yeonsu; Schäckermann, Dorina; Pedotti, Mattia; Kuhn, Philipp; Zock-Emmenthal, Susanne; Wöhrle, Johannes; Kilb, Normann; Herz, Tobias; Becker, Marlies; Grasshoff, Martina; Wenzel, Esther Veronika; Russo, Giulio; Kröger, Andrea; Brunotte, Linda; Ludwig, Stephan; Fühner, Viola; Krämer, Stefan Daniel; Dübel, Stefan; Varani, Luca; Roth, Günter; Čičin-Šain, Luka; Schubert, Maren; Hust, Michael
title: SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
date: 2020-10-02
journal: bioRxiv
DOI: 10.1101/2020.06.05.135921
sha: 760e2e748332150d868883a86f60a2eb2cc2d024
doc_id: 714263
cord_uid: obhm5mc5

COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a novel betacoronavirus discovered in December 2019 and closely related to the SARS coronavirus (CoV). Both viruses use the human ACE2 receptor for cell entry, recognizing it with the Receptor Binding Domain (RBD) of the S1 subunit of the viral spike (S) protein. The S2 domain mediates viral fusion with the host cell membrane. Experience with SARS and MERS coronaviruses has shown that potent monoclonal neutralizing antibodies against the RBD can inhibit the interaction with the virus cellular receptor (ACE2 for SARS) and block the virus cell entry. Assuming that a similar strategy would be successful against SARS-CoV-2, we used phage display to select from the human naïve universal antibody gene libraries HAL9/10 anti-SARS-CoV-2 spike antibodies capable of inhibiting interaction with ACE2. 309 unique fully human antibodies against S1 were identified. 17 showed more than 75% inhibition of spike binding to cells expressing ACE2 in the scFv-Fc format, assessed by flow cytometry and several antibodies showed even an 50% inhibition at a molar ratio of the antibody to spike protein or RBD of 1:1. All 17 scFv-Fc were able to bind the isolated RBD, four of them with sub-nanomolar EC50. Furthermore, these scFv-Fc neutralized active SARS-CoV-2 virus infection of VeroE6 cells. In a final step, the antibodies neutralizing best as scFv-Fc were converted into the IgG format. The antibody STE73-2E9 showed neutralization of active SARS-CoV-2 with an IC50 0.43 nM and is binding to the ACE2-RBD interface. Universal libraries from healthy human donors offer the advantage that antibodies can be generated quickly and independent from the availability of material from recovered patients in a pandemic situation.

COVID-19 patients by single B-cell PCR 18, 19 or using phage display 20, 21 . Human recombinant antibodies were successfully used for the treatment of other viral diseases.

The antibody mAb114 22 and the three antibody cocktail REGN-EB3 23 showed a good efficiency in clinical trials against Ebola virus 24 . The antibody palivizumab is EMA/FDA approved for treatment of a severe respiratory infection of infants caused by the respiratory syncytial virus (RSV) 25,26 and could be used as a guideline to develop therapeutic antibodies against SARS-CoV-2.

Antibody phage display is a powerful tool to generate human antibodies against infectious diseases 27 . We successfully used this technology to develop in vivo protective antibodies against Venezuelan encephalitis virus 28 , Western-equine encephalitis 29,30 , Marburg virus 31 and Ebola Sudan virus 32 . In this work, we generated human recombinant antibodies against the spike proteins of SARS-CoV-2 from a universal, human naive antibody gene library that was constructed before the emergence of SARS-CoV-2. Several scFv-Fc antibodies were identified which efficiently inhibited the binding of the spike protein to ACE2-expressing cells and blocked SARS-CoV-2 infection of VeroE6 cells. The best antibody in the IgG format is a potential candidate for the clinical development of a passive immunotherapy for therapeutic and prophylactic purposes.

SARS-CoV-2 RBD-SD1 (aa319-591) according to Wrapp et al. 2020 33 , S1 subunit (aa14-694), S1-S2 (aa14-1208, with proline substitutions at position 986 and 987 and "GSAS" substitution at the furin site, residues 682-685) and extracellular domain of ACE2 receptor were produced in insect cells using a plasmid based baculovirus free system 34 as well as in Expi293F cells. All antigens with exception of S1-S2 were produced with human IgG1 Fc part, murine IgG2a Fc part or with 6xHis tag in both expression systems. S1-S2 was only produced with 6xHis tag. The extracellular domain of ACE2 was produced with human IgG1 Fc part or mouse IgG2a in Expi293F cells and 6xHis tagged in insect cells. The yields of all produced proteins are given in Table 1 . A graphical overview on all produced proteins is given in Supplementary Data 1. The expressed proteins were analyzed by size exclusion chromatography (SEC) (Supplementary Data 2). S1 as well as S1-S2 were more efficiently produced in insect cells compared to Expi293F cells. RBD-SD1 was produced well in both production systems. The binding of the produced spike domains/proteins to ACE2 was validated by ELISA and flow cytometry analysis on ACE2 positive cells (Table 1) . encoding for the binders was sequenced and unique antibodies were recloned as scFv-Fc fusions.

In detail, three panning strategies were compared. In a first approach (STE70) the lambda (HAL9) and kappa (HAL10) libraries were combined and the antigen S1-hFc (with furin site, produced in High Five cells) was immobilized in PBS. Here, only seven unique antibodies were identified. In a second approach, the selection was performed separately for HAL10 (STE72) and HAL9 (STE73) using S1-hFc as antigen (with furin site, SEC purified, immobilized in carbonate buffer). Here, 90 unique antibodies were selected from HAL10 and 209 from HAL9. In a third approach (STE77 and STE78), S1-hFc produced in Expi293F cells was used (immobilized in carbonate buffer). Here, the panning resulted in only three unique antibodies that were not further analyzed in inhibition assays. An overview is given in Table 2 .

The antibody subfamily distribution was analyzed and compared to the subfamily distribution in the HAL9/10 library and in vivo (Fig. 1) . The phage display selected antibodies mostly originated from the main gene families VH1 and VH3. Only few antibodies were found using VH4. In 96 of the 309 selected antibodies (31%), the V-gene because the S1-S2 was directly labeled with a fluorophore and the signals were not amplified in comparison to RBD with a murine Fc and a fluorophore labeled secondary antibody. Further, ACE2-expressing Expi293F cells present a much higher amount of ACE2-receptor on their surface compared to Calu-3, due to the CMV-mediated expression (data not shown). Taken together these data show that all 17 inhibiting antibodies selected against S1 directly interfered with RBD-ACE2 binding.

Determination of EC50 of the inhibiting antibodies to RBD, S1 and S1-S2

The EC50 of the inhibiting scFv-Fc on RBD, S1 (without furin site) and S1-S2 spike was measured by ELISA. All inhibiting antibodies bound the isolated RBD (Fig. 3) , identifying it as their target on the viral surface. Most of the inhibiting antibodies showed a half-maximal binding in the subnanomolar range for RBD. While STE72-2G4 showed sub-nanomolar EC50 values for RBD and S1, it was discarded due to noticeable cross-reactivity to mFc.

The EC50 on the S1-S2 spike trimer was reduced for most of the antibodies, in comparison to the isolated RBD or S1. scFv-Fc (Fig. 4A , Table 3 ). VeroE6 cells showed pronounced CPE characterised by rounding and detachment clearly visible in phase contrast microscopy upon SARS-CoV-2 infection within 4 days, while uninfected cells maintained an undisturbed confluent monolayer. Virus inoculum pre-incubated with anti-RBD antibodies led to decreased CPE in varying degrees quantified by automated image analysis for cell confluence. All 17 antibodies showed neutralization in this assay. Fig. 4B shows examples for strong (STE73-6C8) and weak (STE73-2C2) neutralizing antibodies and controls.

Eleven scFv-Fc showing a neutralization efficacy of 90% according to the CPE-based neutralization assay were converted into the IgG format. First, their binding was analyzed by titration ELISA on RBD, S1 and S1-S2 (Supplementary Data 6, Table 3 ). Three antibodies lost binding after conversion to IgG (STE72-8A2, STE72-8A6 and STE73-6B10, data not shown), others showed reduced binding of different degrees, while three antibodies retained their binding (STE70-1E12, STE72-4E12 and STE73-2E9). In the next step, the antibodies were tested in the cell-based inhibition assay using RBD (Figure 5A) or S1-S2 ( Figure 5B ). Here, the inhibition was confirmed for STE73-2E9, -9G3, -2G8.

STE73-1B6 showed inhibition of RBD comparable to the latter antibodies, but its activity was almost absent on S1-S2, thus it was not further considered.

The efficiently inhibiting IgGs STE73-2E9, STE73-2G8 and STE73-9G3 were analyzed for their binding to various S1 subunit variants harbouring a panel of recently reported mutations in RBD region and the D614G mutation. Three assays were employed: 1, ELISA ( Figure 6A ), 2, surface plasmon resonance (SPR) and 3, bScreen protein array with S1 11/45 proteins from different sources. All three antibodies lost binding to RBD mutations in the region aa483-486 directly at the RBD-ACE2 interface, showing that mutations in that region affect their epitope on the antigen. There were only minor differences between different approaches, e.g. at positions aa439 and aa476 for STE73-2E9. We then used this information to guide and validate computational docking simulations followed by atomistic molecular dynamics simulations according to protocols developed and well established in our group 35 , obtaining three-dimensional atomic models of the antibody-RBD interaction for these three antibodies ( Figure 6B ). The binding models of the three antibodies to the spike ectodomain are shown in Supplementary Data 7.

As a final step, STE73-2E9, -9G3, -2G8 antibodies were analyzed in a plaque assay using the patient isolate SARS-CoV-2 (Münster/FI110320/1/2020) to determine their neutralization potency. STE73-2E9 showed an IC50 of 0.43 nM in this assay.

Unfortunately, STE73-9G3 and -2G8 did not show high neutralization as IgG ( Figure 7A ).

The neutralizing antibody STE73-2E9 was further characterized by titration ELISA on SARS-CoV-2 spike recombinant constructs ( Figure 7B ) and S1 subunits from different coronaviruses ( Figure 7C) showing that STE73-2E9 is binding specifically SARS-CoV-2 Spike protein in the RBD region. The specific binding to S1/RBD of SARS-CoV-2 was further confirmed by the bScreen protein array binding analysis (data not shown).

The affinity of STE73-2E9 was determined by Surface Plasmon Resonance as 2x10 -9 M for RBD-SD1 ( Figure 7D ) and 9.25 -10 M for the complete spike protein ( Figure 7E ).

The aggregation behaviour of biologicals is a key factor for therapeutic development. implicating that it has benign general physicochemical properties that are a prerequisite for the development into a passive vaccine (supplementary data 8).

For 130 years, antibodies in animal sera or convalescent human plasma were successfully used for the treatment of infectious diseases, starting with the work of Emil von Behring und Shibasaburo Kitasato against diphtheria 35 . However, the efficacy of human plasma derived from convalescent donors depends on the viral pathogen. In case of Ebola, the survival upon treatment with convalescent human plasma was not significantly improved over the control group 36 . On the other hand, reduced mortality and safety was shown for convalescent plasma transfer in case of influenza A H1N1 in 2009 37, 38 . This approach was also used against emerging coronaviruses. While the outcomes were not significantly improved in a very limited number of MERS patients 39 , the treatment was successful for SARS 40, 41 . This approach was also used for COVID-19 with promising results 42 . The mode of action of these polyclonal antibody preparations may vary, including virus neutralization, Fcγ receptor binding mediated phagocytosis or antibody dependent cellular cytotoxicity as well as complement activation [43] [44] [45] . In any serum therapy, the composition and efficacy of convalescent plasma is expected to differ from donor to donor, as well as batch to batch, and sera must be carefully controlled for viral contaminations (e.g. HIV, Hepatitis viruses) and neutralization potency. A convalescent patient can provide 400-800 mL plasma, with 250-300 mL of plasma typically needed per treatment. With two rounds of treatment per patient, this is a grave limitation, since one donor can only provide material for 1-2 patients 42, 43 . Human or humanized monoclonal antibodies are a powerful alternative to polyclonal antibodies derived from convalescent plasma. Following this approach, the humanized antibody Palivizumab was approved in 2009 for treatment and prevention of Respiratory Syncytial Virus (RSV) infections 46 . Other antibodies against viral diseases successfully tested in clinical studies are mAb114 and REGN-EB3 against Ebola disease 24 .

Phage display derived antibodies are typically well established medications: twelve such antibodies are approved by EMA/FDA at the time of writing, a significant increase compared to the six such antibodies approved in 2016 47 . In this work, we used phage display to isolate monoclonal human antibodies capable of neutralizing SARS-CoV-2 from a universal, naive antibody gene library that was generated from healthy donors before the emergence of the SARS-CoV-2 virus. This allowed selection of human antibodies against this virus without the necessity to obtain material from COVID-19 infected individuals.

While most antibodies against SARS-CoV-2 were obtained from convalescent patients with few exceptions 20, 21, 48, 49 our approach demonstrates that human antibodies with functional properties matching those of the antibodies isolated from convalescent patients can be generated without the necessity to wait for material from COVID-19 infected individuals. Therefore, this strategy offers a very fast additional opportunity to respond to future pandemics.

As the human receptor of SARS-CoV and SARS-CoV-2 is ACE2 3 , we focused on antibodies which directly block the interaction of the spike protein with this receptor and antibodies preventing ACE2 binding were shown to potently neutralize the closely related SARS-CoV virus 16 . 309 unique fully human monoclonal antibodies were generated using different panning strategies. The S1 subunit produced in insect cells was better suited for antibody selection than the S1 subunit produced in mammalian cells. cells selected from COVID-19 patients. By contrast, the second most selected V-gene was VH3-53, which was selected in our approach only once. Robbiani et al. also described an overrepresented use of VL6-57, as found in our antibodies as well. However, it has to be noted that VL6 is also overrepresented in our naïve library compared to its in vivo occurrence.

From the initial 309 scFv, 109 were recloned in the scFv-Fc IgG-like bivalent format. Their ability to inhibit binding of fluorescently labelled S1-S2 trimer to ACE2 expressing cells was (open) or "down" (close) position. The "down" conformation can not bind to ACE2, in contrast to the less stable "up" conformation 33 . The RBDs can be in different conformations on the same spike trimer, which offers a possible explanation for the observed effective antibody to spike molar ratios lower than 1:1. This is in accordance with the cryo-EM images recorded by Walls et al. 4 , where they could find half of the recorded trimers with one RBD in the open conformation. We observed that molar ratios for half maximal inhibition were lower for RBD compared to spike protein. For some antibodies, approximately 0.5 antigen binding sites were needed to achieve a 50% inhibition. The fact that the antibodies are more efficient at inhibiting RBD binding to ACE2 rather than S1-S2 trimer binding can be explained with the higher affinity of the antibodies for the isolated RBD compared to the trimeric spike, which in turn points to the presence of partially or completely inaccessible epitopes on the trimer, an occurrence seen in other viruses. This

is similar to what was reported by Pinto et al. 17 who also showed a lower affinity of the antibody S309 for spike compared to RBD.

Inhibition of ACE2 binding was stronger on the human lung cells Calu-3, which better represent the in vivo situation than transiently ACE2 overexpressing cells. Nevertheless, we did the titration assays on ACE2 overexpressing Expi293F cells because these seemed to allow a better quantitative discrimination of inhibiting potency.

Antibody combinations can have a synergistic effect as previously described for toxins and viruses 32,53-55 . This approach may also avoid formation of viral escape mutants. Here, the best combinations showed a significantly improved inhibition efficacy, at least when using an excess of antibodies (Ab:Agmolar ratio 30:1).

All of the 17 scFv-Fc were tested in neutralization assays using a SARS-CoV-2 strain isolated from a patient and all antibodies showed a degree of neutralization in this assay.

While this study did not aim to define the lowest effective concentration of individual antibodies in limiting dilution conditions, all tested antibodies showed a clear and measurable effect at a relatively low concentration. Therefore, our approach provided a rapid selection of antiviral antibodies.

In a next step, we converted eleven antibodies with the best neutralization efficacy according to the cytopathic assay into the IgG format. It was completely unexpected that most antibodies lost efficacy in the inhibition assay after conversion from scFv-Fc to IgG including antibodies like STE70-1E12 without loss of affinity according to the titration ELISA. These results are in contrast to former results where none 54 or only a low percentage 55,56 of antibodies lost efficacy after conversion from scFv-Fc to IgG.

Nevertheless, three antibodies showed a good inhibition in the cell-based assay and did not bind to the region of aa483-486 known for RBD mutations from publications 19,57 and from GISAID database (www.gisaid.org). Experimentally validated computational docking 17/45 shows that these antibodies still at least partially occupy the ACE2 binding site on the RBD, thus likely achieving direct inhibition of virus-ACE2 interaction. The binding sites of antibody BD368-2 18 , B38 58 and REGN10933 59 also overlap with the RBD ACE2 binding interface. The neutralizing antibody STE73-2E9 was specific for SARS-CoV-2 and we conclude that this antibody is a suitable candidate for the development of passive immunotherapy for the treatment of COVID-19. It could be used therapeutically to prevent individuals from being hospitalized in intensive care units (ICUs), but also prophylactically, to protect health care workers or risk groups that do not respond to vaccination. Before clinical application, the risk of antibody-dependent enhancement of disease (ADE) has to be considered for COVID-19. In contrast to antibodies against Ebola where ADCC is important for protection 22 , antibodies directed against the spike protein of SARS-CoV-2 may lead to ADE [60] [61] [62] . SARS cause an acute lung injury which is also driven by immune dysregulation and inflammation caused by anti-spike antibodies 63 . While, Quinlan et al. 64 described that animals immunized with RBD SARS-CoV-2 did not mediate ADE and suggested for vaccines the use of RBD, some of the monoclonal antibodies we analyzed in this study lead to an increased binding of the spike protein to ACE2 positive cells. A possible explanation could be multimerization of the spike by antibody 'cross-linking' in this assay or the stabilization of an infection-promoting conformation by the antibodies. These aspects need to be carefully considered in any development of therapeutic antibodies, we suggest to focus on RBD and/or the use of silenced Fc parts with deleted Fcγ and C1q binding [65] [66] [67] for safety reasons.

In conclusion, we report the successful isolation and characterization of a fully human, recombinant anti-spike neutralizing monoclonal antibody from naïve phage display libraries. Our approach demonstrates how neutralizing antibodies can be efficiently selected in a rapid time frame and without the need of convalescent patient material.

Furthermore, the strategy we used efficiently targeted the spike:ACE interface allowing the selection of directly blocking antibodies.

Production in Expi293F cells was performed using pCSE2.5-His-XP, pCSE2.6-hFc-XP or pCSE2.6-mFc-XP 68 where the respective single chain variable fragment of the antibodies or antigens were inserted by NcoI/NotI (NEB Biolabs) digestion. Antigen production in High Five insect cells was performed using NcoI/NotI compatible variants of the OpiE2 plasmid 69 containing an N-terminal signal peptide of the mouse Ig heavy chain, the respective antigen and C-terminal either 6xHis-tag, hFc or mFc. Single point mutations in S1-HIS constructs were inserted through site-directed mutagenesis using overlapping primers according to Zheng et al. 70 with slight modifications: S7 Fusion polymerase (Mobidiag, Espoo, Finland) with the provided GC buffer and 3%DMSO was used for the amplification reaction. (30%)) were mixed). After addition of 1 N H2SO4 to stop the reaction, absorbance at 450 nm with a 620 nm reference wavelength was measured in an ELISA plate reader (BioTek Instruments, Epoch).

To verify the ACE2-antigen interaction on living cells, Expi293F cells were transfected according to the protocol above using pCSE2.5-ACE2fl-His and 5% eGFP plasmid. Two days after transfection, purified S1-S2-His, S1-His or RBD-His were labelled using 

The antibody selection was performed as described previously with modifications 71 . In brief, for panning procedure, the antigen was immobilized on a High binding 96 well plate (Corning, Costar). 5 µg of S1-hFc (produced in High Five cells) was diluted in carbonate puffer (50 mM NaHCO3/Na2CO3, pH 9.6) and coated onto the wells at 4°C overnight. Next, the wells were blocked with 350 µL 2% MBPST (2% (w/v) milk powder in PBS; 0.05% Tween20) for 1 h at RT and then washed 3 times with PBST (PBS; 0.05% Tween20).

Before adding the libraries to the coated wells, the libraries (5x10 10 2xYT-GA (1.6% (w/v) Tryptone; 1 % (w/v) Yeast extract; 0.5% (w/v) NaCl (pH 7.0), 100 mM D-Glucose, 100 µg/mL ampicillin) was added and incubated for 1 h at 37°C and 650 rpm, followed by addition of 1x10 10 cfu M13KO7 helper phage. Subsequently, the infected bacteria were incubated for 30 min at 37°C followed by 30 min at 37°C and 650 rpm before centrifugation for 10 min at 3220xg. The supernatant was discarded and the pellet resuspended in fresh 2xYT-AK (1.6% (w/v) Tryptone; 1 % (w/v) Yeast extract; 0.5% (w/v) NaCl (pH 7.0), 100 µg/mL ampicillin, 50 µg/mL kanamycin). The antibody phage were amplified overnight at 30°C and 650 rpm and used for the next panning round. In total four panning rounds were performed. In each round, the stringency of the washing procedure was increased (20x in panning round 2, 30x in panning round 3, 40x in panning round 4) and the amount of antigen was reduced (2.5 µg in panning round 2, 1.5 µg in panning round 3 and 1 µg in panning round 4). After the fourth as well as third panning round single clones containing plates were used to select monoclonal antibody clones for the screening ELISA.

Soluble antibody fragments (scFv) were produced in 96-well polypropylene MTPs (U96 PP, Greiner Bio-One) as described before 55, 71 . Briefly, 150 μL 2xYT-GA was inoculated with the bacteria bearing scFv expressing phagemids. MTPs were incubated overnight at For the ELISA, 100 ng of antigen was coated on 96 well microtiter plates (High binding, Greiner) in PBS (pH 7.4) overnight at 4°C. After coating, the wells were blocked with 2% MPBST for 1 h at RT, followed by three washing steps with H2O and 0.05% Tween20.

Supernatants containing secreted monoclonal scFv were mixed with 2% MPBST (1:2) and incubated onto the antigen coated plates for 1 h at 37°C followed by three H2O and 0.05% Tween20 washing cycles. Bound scFv were detected using murine mAb 9E10 which (30%)) were mixed). After stopping the reaction by addition of 1 N H2SO4, absorbance at 450 nm with a 620 nm reference was measured in an ELISA plate reader (Epoch, BioTek).

Monoclonal binders were sequenced and analyzed using VBASE2 (www.vbase2.org) 72 and possible glycosylation positions in the CDRS were analyzed according to Lu et al 73 .

The inhibition tests in cytometer on EXPI293F cells were performed based on the protocol for validation of spike protein binding to ACE2 (see above) but only binding to S1-S2-His and RBD-mFc antigen (High Five cell produced) was analyzed. The assay was done in 

ELISA were essentially performed as described above in "Screening of monoclonal recombinant binders using E.coli scFv supernatant". For titration ELISA the purified scFv-hFc were titrated from 3.18 µg/mL-0.001 ng/mL on 30ng/well of the following antigens: S1-S2-His (High Five cell produced), RBD-mFc (High Five cell produced), S1-mFc (High Five cell produced) and TUN219-2C1-mFc (as control for unspecific Fc binding). In addition, all scFv-hFc were also tested only at the highest concentration (3.18 µg/mL) for unspecific cross-reactivity on Expi293F cell lysate (10 4 cells/well), BSA (1% w/v) and lysozyme. ScFv-hFc or IgG were detected using goat-anti-hIgG(Fc)-HRP (1:70000, A0170, Sigma). Titration assays were performed using 384 well microtiter plates (Costar) using Precision XS microplate sample processor (BioTek), EL406 washer dispenser (BioTek) and BioStack Microplate stacker (BioTek). EC50 were calculated with by GraphPad Prism Version 6.1, fitting to a four-parameter logistic curve. The binding of antibodies to S1 subunit His-tagged constructs containing mutations in the RBD region and the crossreactivity to Spike proteins of other coronaviruses was tested as described above. S1-HIS proteins from SARS-CoV-2 (expressed in HEK cells), SARS-CoV-1, MERS, HCoV HKU1,

HCoV NL63, HCoV 229E were acquired commercially (Sino Biologicals products 40591-V08H, 40150-V08B1, 40069-V08H, 40021-V08H, 40601-V08H, 40600-V08H).

The antibody structures were modelled according to the canonical structure method using the RosettaAntibody program 74 as previously described 75 and docked to the experimental structure of SARS-CoV-2 S protein receptor binding domain (RBD, PDBid: 6M17) 6 .

Docking was performed using the RosettaDock 3.12 software 76 as previously described 77 .

Briefly, each antibody was manually placed with the CDR loops facing the RBD region containing the residues identified by the peptide mapping experiment. The two partners were moved away from each other by 25Å and then brought together by the computational docking algorithm, obtaining thousands of computationally generated complexes (typically 15,000). The antibody/RBD complexes were structurally clustered and then selected according to the scoring function (an estimate of energetically favourable solutions) and agreement with the peptide mapping data. Selected complexes were further optimized by a docking refinement step and molecular dynamics simulations.

VeroE6 cells (ATCC CRL-1586) were seeded at a density of 6*10 4 /well onto cell culture 96-well plates (Nunc, Cat.#167008). Two days later, cells reached 100% confluence. antibody/virus mix and phase contrast images were taken automatically using a Sartorius IncuCyte S3 (10x objective, two hours image intervals, 4 images per well) housed in a HeraCell 150i incubator (37°C, 100% humidity, 5% CO2). Image data was quantified with the IncuCyte S3 GUI tools measuring the decrease of confluence concomitant with the cytopathic effect of the virus in relation to uninfected controls and controls without antibody and analyzed with GraphPad Prism 8. Given is the median of the inhibition.

For titration, antibodies were diluted in 1/√10 steps and mixed with a fixed inoculum of SARS-CoV-2 (100-150 pfu) in a total volume of 500 µl of Vero E6 medium. After one hour incubation at 37°C, cells were infected with the antibody/virus mix, incubated for one hour and then overlaid with Vero E6 medium containing 1.5% methyl-cellulose. Three days postinfection, wells were imaged using a Sartorius IncuCyte S3 (4x objective, whole-well scan) and plaques were counted from these images.

For IgG production, selected antibodies were converted into the human IgG1 format by subcloning of VH in the vector pCSEH1c (heavy chain) and VL in the vector pCSL3l/pCSL3k (light chain lambda/kappa) 78 , adapted for Golden Gate Assembly procedure with Esp3I restriction enzyme (New England Biolabs). EXPI293F (Thermo Fisher Scientific) cells were transfected with 12.5 µg of both vectors in parallel in a 1:1 ratio. For production, the transfected EXPI293F cells were cultured in chemically defined medium F17 (Thermo Fisher Scientific) supplemented with 0.1% pluronic F68 (PAN-Biotech,) and 7.5 mM L-glutamine (Merck) for seven days. A subsequent protein A purification was performed as described above.

Affinity determination by surface plasmon resonance (SPR)

The antibodies binding properties were analyzed at 25 °C on a Biacore ™ 8K instrument (GE Healthcare) using 10mM HEPES pH 7.4, 150mM NaCl, 3mM EDTA and 0.005% Tween-20 as running buffer. SARS-CoV2 RBDs, wild-type and different mutants, or full Sprotein, were immobilized on the surface of a CM5 chip through standard amine coupling.

Increasing concentration of antibodies (6.25-12.5-25-50-100nM) were injected using a Single-cycle kinetics setting and analyte responses were corrected for unspecific binding and buffer responses. Curve fitting and data analysis were performed with Biacore™ Insight Evaluation Software.

2 nL of the proteins were printed as quadruplicates onto PDITC coated bScreen slides with a pitch of 700µm using a SciFlexArrayer (Scienion AG) in non-contact mode. The following proteins were spotted on the array: S1-S2, SARS-CoV-2, High5 (this work); S1, SARS-CoV-2, HEK293 (Sino Biological 40591-V08H); S1, SARS-CoV-2, Baculovirus (Sino Biological 40591-V08B1); S1-RBD, SARS-CoV-2, HEK293 (Sino Biological 40592-V08H); S1-humFc, SARS-CoV-2, HEK293 (Sino Biological 40591-V02H); S1S2, SARS-CoV-2, Baculovirus (Sino Biological 40589-V08B1); S2, SARS-CoV-2, Baculovirus (Sino Biological 40590-V08B); S1-RBD mFc, SARS-CoV-2, HEK293 (Sino Biological 40592-V05H); S1-RBD32, SARS-CoV-2, High5 (this work); S1-RBD25, SARS-CoV-2, High5 (this work); S1-RBD22, SARS-CoV-2, High5 (this work); S2, SARS-CoV-2, High5 (this work); S1, SARS-CoV-2, High5 (this work); S1 mFc, SARS-CoV-2, High5 (this work); S1-RBD32 mFc, SARS-CoV-2, High5 (this work); S1(E484K), SARS-CoV-2, High5 (this work); S1(F486V), SARS-CoV-2, High5 (this work); S1(N438K), SARS-CoV-2, High5 (this work); S1(G458R), SARS-CoV-2, High5 (this work); S1S2(D614G), SARS-CoV-2, High5 (this 29/45 work); S1-RBD(V367F), SARS-CoV-2, HEK293 (Sino Biological 40592-V08H1); S1-RBD(V483A), SARS-CoV-2, HEK293 (Sino Biological 40592-V08H5); S1-RBD(R408I), SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H8); S1-RBD(G476S), SARS-CoV-2, HEK293 (Acro Biosystems SPD-C52H4); S1-RBD(N354D, D364Y), SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H3); S1-RBD(N354D), SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H5); S1-RBD(W436R), SARS-CoV-2, HEK293 (Acro Biosystems SPD-S52H7); S1-RBD, SARS-CoV-2, Baculovirus (Sino Biological 40592-V08B); S1(D614G), SARS-CoV-2, HEK293 (Sino Biological 40591-V08H3);; S1-S2, SARS, HEK293 (Acro Biosystems SPN-S52H5); S1, SARS, HEK293 (Acro Biosystems SIN-S52H5); S1-RBD, SARS, HEK293 (Acro Biosystems SPD-S52H6); S1-RBD, MERS, Baculovirus (Sino Biological 40071-V08B1); S1, MERS, HEK293 (Sino Biological 40069-V08H); N, MERS, Baculovirus (Sino Biological 40068-V08B); S1, HCoV-229E, HEK293

(Acro Biosystems SIN-V52H4); S1, HCoV-NL63, HEK293 (Acro Biosystems SIN-V52H3); S1, HCoV-HKU1, HEK293 (Sino Biological 40602-V08H); Streptavidin Cy5 (Thermo Fisher 434316); bBSA, (Thermo Fisher 29130), BSA (Carl Roth GmbH 8076.4). Protein concentration was adjusted to 200µg/mL, with the following exceptions: S1-RBD(E484K) 50 µg/mL, S1-RBD(F486V) 100 µg/mL, S1-RBD(N439K) 138 µg/mL, S1-RBD(G485R) 91 µg/ml. A bscreen was used for label-free measurement of antibody binding to the protein arrays. PBS BSA (1mg/ml) was used as sample as well as washing buffer. The flow-rate was set to 3µL/s. The measurement was performed in 3 steps -1st step blocking solution (50% PBS BSA 1/mg/mL , 50% Superblock (Thermo Scientific -Cat No: 37515)); 2nd step neutralizing SARS-CoV-2 antibody 8µg/mL; 3rd step goat anti human Alexa 546 antibody 5µg/mL (Invitrogen -Cat No: A-21089). Each step consisted of 150s baselining, 333s association, 300s dissociation. The label-free signals of the association phase of the anti human step were used for data generation. This was done by subtracting the signal mean 30/45 value from 30s to 20s before the association phase from the signal mean value from 20s to 30s after the association phase.

The antibody structures were modelled according to the canonical structure method using the RosettaAntibody program 74 as previously described 75 and docked to the experimental structure of SARS-CoV-2 S protein receptor binding domain (RBD, PDBid: 6M17) 6 .

Docking was performed using the RosettaDock 3.12 software 76 as previously described 77 .

Briefly, each antibody was manually placed with the CDR loops facing the RBD region inhibiting scFv-Fc on RBD (fusion protein with murine Fc part), S1 (fusion protein with murine Fc part) or S1-S2 (fusion protein with His tag). Sequence SARS-CoV-2 (Gene bank QHD43416). An unrelated antibody with murine Fc part (TUN219-2C1), human HEK293 cell lysate, BSA or lysozyme were used as controls. EC50 were calculated with GraphPad Prism Version 6.1, fitting to a four-parameter logistic curve. to other Coronavirus spike proteins analzyed by ELISA. S1-HIS SARS-CoV-2 Hi5 was produced in house. S1-HIS SARS-CoV-2 HEK and all other coronaviruses S1 domain proteins were obtained commercially. (D and E) Kinetic parameters determination through single cycle kinetic titration SPR of STE73-2E9 IgG on HEK cell produced RBD-SD1 and S1-S2, respectively (concentrations: 200, 100, 50, 25, 12.5, 6.25 nM). Max. production yields of SARS-CoV-2 spike protein/domains in insect cells (High Five) and mammalian cells (Expi293F). Proteins with His-tag produced in High Five cells and S1-hFc* were additionally purified by SEC. * with Furin site. RBD S1 S1-S2 RBD S1 S1-S2 IC 50 72 . The EC50 were measured on 30 ng immobilized RBD-mFc, S1-mFc, S1-S2-His (trimer) by ELISA. The IC50 was measured by flow cytometry using 50 nM (in relation to monomer) S1-S2 trimer, respectively 10 nM RBD and ACE2 positive cells. The molar ration of antibody binding site: S1-S2 or RBD is given for 50% inhibition. n.a.: not applicable. CPE based neutralization assay was performed with 250 pfu/well SARS-CoV-2 and 1 µg/ml (~100 nM) (median neutralization %). EC50 were calculated with GraphPad Prism Version 6.1, fitting to a four-parameter logistic curve. IC50 values were calculated using Logistic5 fit of Origin.

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure, Function, and Evolution of Coronavirus Spike Proteins

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

A human monoclonal antibody blocking SARS-CoV-2 infection

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Potent neutralizing antibodies against SARS-CoV-2 identified by highthroughput single-cell sequencing of convalescent patients' B cells

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

Neutralizing Antibodies Isolated by a site-directed Screening have Potent 36

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Hyperimmune IV immunoglobulin treatment: a multicenter doubleblind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Use of convalescent plasma therapy in SARS patients in Hong Kong

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Dissecting antibody-mediated protection against SARS-CoV-2

Palivizumab in the prevention of respiratory syncytial virus disease

Phage display-derived human antibodies in clinical development and therapy

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models

Isolation of and Characterization of Neutralizing Antibodies to Covid-19 from a Large Human Naïve scFv Phage Display Library

Generation and analysis of the improved human HAL9/10 antibody phage display libraries

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library

Development of an antibody cocktail for treatment of Sudan virus infection

The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies

Human antibodies neutralizing diphtheria toxin in vitro and in vivo

Rise and fall of an anti-MUC1 specific antibody

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

The potential danger of suboptimal antibody responses in COVID-19

Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE)

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

The SARS-CoV-2 Receptor-Binding Domain Elicits a Potent Neutralizing Response Without Antibody-Dependent Enhancement

Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R

High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells

Genomic Analysis and Isolation of RNA Polymerase II Dependent Promoters from Spodoptera frugiperda

An efficient one-step site-directed and sitesaturation mutagenesis protocol

Parallelized Antibody Selection in Microtiter Plates

Analysis of single chain antibody sequences using the VBASE2 Fab analysis tool

Deamidation and isomerization liability analysis of 131 clinical-stage antibodies

Modeling and docking of antibody structures with Rosetta

Computational docking of antibodyantigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin

Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations

Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking

The influence of antibody fragment format on phage display based affinity maturation of IgG

GROMACS: fast, flexible, and free

A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties

We kindly acknowledge the support of the European Union for the ATAC ("antibody therapy against corona", Horizon2020 number 101003650) consortium and the MWK Niedersachsen (14-76103-184 CORONA-2/20). L. Varani gratefully acknowledges support from SNF and Lions Club Monteceneri. Work was also supported by the Deutsche